Press Releases
U.S. FDA Grants Priority Review to Janssen for Daratumumab...
If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients Janssen Research & Development, LLC (Janssen) announced today...
Press Releases
Your Story, Your HIV Wisdomâ„¢ Brings Together HIV Voices...
Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression Seeking and sharing...
Press Releases
Johnson & Johnson Announces BARDA Funding Award to Accelerate...
Johnson & Johnson (NYSE: JNJ) announced today that Crucell Holland B.V., one of its Janssen Pharmaceutical Companies, has been awarded $28.5 million from The Biomedical...
Press Releases
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab...
Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer. ...
Press Releases
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational...
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines ...
Press Releases
New Directions in Breast Conserving Surgery – An Interview...
Additionally, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from a...
Press Releases
SABCS15: ONT-380 Phase I results support progression to Phase...
Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial efficacy...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.